MOTS-c Dosage & Reconstitution Guide: mg to mcg Chart
MOTS-c Peptide
MOTS-c is a mitochondrial-derived peptide studied for metabolic regulation, glucose-related signaling, exercise biology, mitochondrial stress responses, and aging-related pathways. Human research has demonstrated relationships between naturally occurring MOTS-c, exercise, and metabolic health, while most research involving administration of exogenous MOTS-c remains preclinical.
How MOTS-c Works
Mitochondrial Signaling → Cellular Stress Response → AMPK-Related Pathways → Metabolic Adaptation
MOTS-c is associated with cellular energy sensing, AMPK-related signaling, glucose metabolism, and adaptation to metabolic stress. Research suggests that MOTS-c can act as a mitochondrial signaling molecule rather than simply functioning through a single surface receptor. Human studies have measured changes in naturally occurring MOTS-c during exercise and metabolic interventions, while many of the stronger performance and metabolic findings following exogenous administration come from animal and cellular research.
Standard Research Protocol (Titration)
Important Evidence Distinction:
The protocol below preserves a commonly discussed MOTS-c research-use titration framework. Published human studies have not established the 200 mcg → 400 mcg → 600 mcg → 800 mcg → 1 mg progression as a clinically validated injectable dosing schedule.
The protocol below preserves a commonly discussed MOTS-c research-use titration framework. Published human studies have not established the 200 mcg → 400 mcg → 600 mcg → 800 mcg → 1 mg progression as a clinically validated injectable dosing schedule.
10 mg Vial + 3.0 mL BAC Water → 1 Unit ≈ 33.3 mcg → Gradual Research-Use Build
Standard Research-Use Setup
Vial10 mg
Water3.0 mL bacteriostatic water
Concentration3.33 mg/mL
Conversion1 unit ≈ 33.3 mcg
Weeks 1–2
Starting Dose
Dose200 mcg
Units6 units
FrequencyDaily
Volume0.06 mL
Weeks 3–4
Titration
Dose400 mcg
Units12 units
FrequencyDaily
Volume0.12 mL
Weeks 5–6
Build
Dose600 mcg
Units18 units
FrequencyDaily
Volume0.18 mL
Weeks 7–8
Higher Range
Dose800 mcg
Units24 units
FrequencyDaily
Volume0.24 mL
Weeks 9–10
Target Research-Use Dose
Dose1,000 mcg (1 mg)
Units30 units
FrequencyDaily
Volume0.30 mL
Why use a titration?
Research-Use Rationale
Gradual dose escalation is commonly used in MOTS-c research-use
frameworks to introduce the compound conservatively and make response
easier to track.
Evidence Limitation
Controlled human research has not established that titrating MOTS-c in
this manner is required for metabolic adaptation, safety, or superior
outcomes.
What the Human Research Actually Shows
Human Evidence Context
Human studies have measured naturally occurring MOTS-c in blood and skeletal muscle rather than establishing a therapeutic injectable dose.
Acute endurance exercise has been shown to increase circulating mitochondrial-derived peptides, including MOTS-c, in human participants.
Exercise-intervention studies have also examined relationships between endogenous MOTS-c, body composition, metabolic health, and physical function.
Human metabolic studies have reported relationships between circulating MOTS-c, insulin, lipid exposure, and exercise.
These findings demonstrate that MOTS-c participates in human exercise and metabolic biology, but they do not establish an injectable MOTS-c treatment protocol.
Preclinical Administration Research
Experimental administration of MOTS-c in animal models has produced findings involving glucose metabolism, insulin sensitivity, exercise capacity, muscle homeostasis, and metabolic stress responses.
Animal research has also reported improved physical capacity and exercise-related performance after exogenous MOTS-c administration.
Those preclinical findings cannot be directly converted into a standardized human dose, cycle, or expected outcome.
Why this matters:
MOTS-c has meaningful human biology research, but that is different from having a validated injectable human protocol. The dosing frameworks shown on this page are preserved as research-use references and should remain separate from what human studies have actually demonstrated.
MOTS-c has meaningful human biology research, but that is different from having a validated injectable human protocol. The dosing frameworks shown on this page are preserved as research-use references and should remain separate from what human studies have actually demonstrated.
How to Use MOTS-c (Research-Use Framework)
Common Research-Use Structure
Typical Cycle Length
8–12 weeks
Extended Option
Up to 16 weeks
Research-Use Route
Subcutaneous
Common Sites
Abdomen, thighs, upper arms
Timing Notes
Morning administration is commonly discussed in metabolic or performance-focused research-use frameworks.
Some research-use approaches place MOTS-c around periods of exercise or higher metabolic demand.
Published human research has not established an optimal time of day for exogenous MOTS-c administration.
A specific morning-versus-evening advantage has not been demonstrated in controlled human dosing trials.
Common Research Contexts
Metabolic-support research
Body-composition research
Exercise and endurance research
Mitochondrial and cellular-energy research
Aging and metabolic-stress research
Simple Strategy:
MOTS-c is commonly structured as a defined metabolic or mitochondrial research phase rather than indefinite continuous exposure. The timing, route, and cycle lengths above represent research-use conventions rather than an established human therapeutic protocol.
MOTS-c is commonly structured as a defined metabolic or mitochondrial research phase rather than indefinite continuous exposure. The timing, route, and cycle lengths above represent research-use conventions rather than an established human therapeutic protocol.
Research-Use Dose Range
Lower Daily Range → Gradual Exposure → Higher Weekly Totals → Experimental Framework
Dose Range Context
Weekly Range
5–10 mg total
Administration
Usually divided across the week
Common Daily Pattern
200 mcg to 1 mg
Important Evidence Distinction:
The 200 mcg–1 mg daily range and 5–10 mg weekly total are research-use references. Published human MOTS-c research has not established these amounts through a standardized injectable dose-ranging or dose-finding program.
Much of the evidence involving administration of exogenous MOTS-c comes from cellular and animal models rather than controlled human treatment trials.
The 200 mcg–1 mg daily range and 5–10 mg weekly total are research-use references. Published human MOTS-c research has not established these amounts through a standardized injectable dose-ranging or dose-finding program.
Much of the evidence involving administration of exogenous MOTS-c comes from cellular and animal models rather than controlled human treatment trials.
Reconstitution & Dosing (10 mg Vial)
Reconstitution & Dosing
Vial10 mg
Water3.0 mL bacteriostatic water
Concentration3.33 mg/mL
Conversion1 unit ≈ 33.3 mcg
Dose Reference
6 units ≈ 200 mcg
12 units ≈ 400 mcg
18 units ≈ 600 mcg
24 units ≈ 800 mcg
30 units ≈ 1 mg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Add slowly down the inside wall of the vial
Gently swirl rather than shaking vigorously
Allow the peptide to dissolve completely
Label with the reconstitution date and concentration
Refrigerate after mixing
Protect from unnecessary heat and light exposure
Reconstitution Context:
The 10 mg + 3.0 mL bacteriostatic-water setup is a research-use preparation that provides convenient syringe conversions. Published human MOTS-c research has not established this dilution ratio or BAC-water preparation as a standardized pharmaceutical formulation.
The 10 mg + 3.0 mL bacteriostatic-water setup is a research-use preparation that provides convenient syringe conversions. Published human MOTS-c research has not established this dilution ratio or BAC-water preparation as a standardized pharmaceutical formulation.
Storage & Handling
Research-Use Storage
Lyophilized Material
Cold, dry, light-protected storage is commonly used for research peptides.
Frozen storage is commonly discussed for longer-term research storage.
Refrigerated storage may be used for shorter-term handling depending on supplier guidance.
Reconstituted Material
Refrigerated storage at 2–8°C is commonly used after reconstitution.
A 4–6 week window is commonly discussed in research-use settings.
Some research-use sources use shorter handling windows when prioritizing stability.
Storage Precautions
Protect from light
Avoid repeated warming and cooling cycles
Minimize unnecessary room-temperature exposure
Follow product-specific stability information whenever available
Evidence Limitation:
MOTS-c does not have an approved injectable formulation with a universal post-reconstitution shelf-life standard. Exact expiration windows depend on formulation, diluent, sterility, concentration, packaging, and storage conditions.
MOTS-c does not have an approved injectable formulation with a universal post-reconstitution shelf-life standard. Exact expiration windows depend on formulation, diluent, sterility, concentration, packaging, and storage conditions.
Time Between Cycles
Research Phase → Break → Reassess → Repeat if Appropriate
Research-Use Cycle Structure
Cycle Length
4–8 weeks on
Time Off
2–4 weeks off
Common Research Structures
Option 1
4–8 weeks on, 2–4 weeks off
Common structured research-use framework
Option 2
2–4 week shorter phase
Used in shorter metabolic or performance-focused research frameworks
Option 3
Run during a defined stack phase, then reassess
Often discussed alongside other mitochondrial or metabolic research compounds
When to Reassess Sooner
The defined research goal has been reached
No additional change is being observed
Unexpected effects or poor tolerability occur
Use is continuing without a defined research purpose
Evidence Distinction:
The 4–8 week cycle and 2–4 week break are research-use conventions. Published human evidence does not establish that MOTS-c requires a specific break to “reset,” “resensitize,” or maintain responsiveness.
The 4–8 week cycle and 2–4 week break are research-use conventions. Published human evidence does not establish that MOTS-c requires a specific break to “reset,” “resensitize,” or maintain responsiveness.
What MOTS-c Is Being Studied For
Metabolic regulation and cellular-energy signaling
Glucose metabolism and insulin-related pathways
Exercise adaptation and physical performance
Mitochondrial stress-response signaling
Muscle homeostasis and age-related physical decline
Aging and longevity-related biology
Benefits & Research Findings
Human research shows that endogenous MOTS-c responds to exercise and metabolic conditions.
Human studies have identified relationships between circulating MOTS-c, insulin signaling, lipid exposure, and exercise.
Preclinical studies have reported improvements in glucose metabolism and insulin-related pathways following exogenous MOTS-c administration.
Animal research has reported improvements in exercise capacity and physical performance.
MOTS-c is being studied in mitochondrial stress-response, muscle-homeostasis, and aging-related pathways.
Human vs. Preclinical Evidence:
The strongest intervention findings involving injected or otherwise administered MOTS-c currently come from animal and cellular studies. Human studies primarily demonstrate that naturally occurring MOTS-c is involved in exercise and metabolic biology. Those findings do not yet establish the same benefits from exogenous injectable MOTS-c.
The strongest intervention findings involving injected or otherwise administered MOTS-c currently come from animal and cellular studies. Human studies primarily demonstrate that naturally occurring MOTS-c is involved in exercise and metabolic biology. Those findings do not yet establish the same benefits from exogenous injectable MOTS-c.
Potential Side Effects & Safety Limitations
Human safety data for exogenous injectable MOTS-c remain limited.
A standardized adverse-effect profile has not been established through large controlled human trials.
Injection-site reactions are possible with subcutaneous research preparations, but MOTS-c-specific incidence rates are not established.
Informally reported fatigue, appetite changes, or energy fluctuations should not be treated as established clinical adverse effects.
Long-term effects of repeated exogenous MOTS-c exposure in humans remain unknown.
Stacking Strategies
MOTS-c → Metabolic Signaling
NAD+ → Cellular Energy Support
SS-31 → Mitochondrial Research
NAD+ → Cellular Energy Support
SS-31 → Mitochondrial Research
Research-Use Frameworks
Energy: MOTS-c + NAD+
Longevity: MOTS-c + Epitalon
Mitochondrial Support: MOTS-c + SS-31
Research-Use Context:
These combinations are research-use stacking frameworks based on different proposed metabolic, cellular-energy, and mitochondrial pathways.
Controlled human trials have not established these combinations as clinically validated stacks or demonstrated that combining them produces better outcomes than studying the compounds individually.
These combinations are research-use stacking frameworks based on different proposed metabolic, cellular-energy, and mitochondrial pathways.
Controlled human trials have not established these combinations as clinically validated stacks or demonstrated that combining them produces better outcomes than studying the compounds individually.
Important Notes
MOTS-c is a mitochondrial-derived peptide naturally encoded within mitochondrial DNA and involved in metabolic and cellular-stress signaling.
Published human research has largely focused on naturally occurring MOTS-c levels, exercise-related changes, metabolic associations, and aging biology rather than establishing an injectable therapeutic dosing protocol.
The 200 mcg → 400 mcg → 600 mcg → 800 mcg → 1 mg daily progression shown on this page is preserved as a research-use framework and is not a clinically validated human titration schedule.
The 5–10 mg weekly total sometimes discussed in research-use settings is also an experimental reference rather than an established human clinical dose.
Much of the evidence involving exogenous MOTS-c and improvements in glucose metabolism, exercise capacity, physical performance, and metabolic stress comes from cellular and animal research.
Human findings showing changes in circulating or skeletal-muscle MOTS-c after exercise do not establish that injected MOTS-c produces the same outcomes.
The 4–8 week, 8–12 week, and extended-cycle frameworks shown on this page are research-use conventions rather than clinically established cycle lengths.
A required 2–4 week break or biologic need to reset or resensitize after MOTS-c use has not been established in controlled human research.
Morning or exercise-related timing is commonly discussed in research-use settings, but no specific time of day has been validated as superior through human dosing trials.
Research-vial reconstitution, bacteriostatic-water ratios, syringe conversions, and storage windows shown on this page should be treated as research-use handling information rather than an approved pharmaceutical preparation standard.
Research vs. Human Evidence:
MOTS-c has meaningful human biology research, but that is different from having an established injectable human treatment protocol. This page preserves commonly discussed research-use dosing, cycling, reconstitution, and stacking frameworks while clearly separating them from what published human studies have actually established.
MOTS-c has meaningful human biology research, but that is different from having an established injectable human treatment protocol. This page preserves commonly discussed research-use dosing, cycling, reconstitution, and stacking frameworks while clearly separating them from what published human studies have actually established.
Important Disclaimer
MOTS-c is an investigational compound. The research-use dosing, reconstitution, cycle, and stacking information shown on this page is educational and should be distinguished from established human clinical treatment protocols.
Research & References
Primary Research
- Lee C, Zeng J, Drew BG, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis. Nature Communications. 2021.
- Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018.
- Wan W, Zhang L, Lin Y, et al. Mitochondria-Derived Peptide MOTS-c: Effects and Mechanisms Related to Stress, Metabolism and Aging. Journal of Translational Medicine. 2023.
Research Note: MOTS-c dosing protocols used by non-prescription sources are not standardized by human clinical trials; most published research on MOTS-c to date involves preclinical and mechanistic studies with only limited human data.
Comments
Post a Comment